JMPWA
CRNX icon

JP Morgan Private Wealth Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,354
Closed -$349K – 1729
2023
Q2 		$349K Sell
19,354
-407
-2% -$8.12K ﹤0.01% 1177
2023
Q1 		$317K Buy
19,761
+545
+3% +$10.1K ﹤0.01% 1658
2022
Q4 		$352K Buy
+19,216
New +$339K ﹤0.01% 1602

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Private Wealth Advisors's CRNX Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2023, closing a stake of 19,354 shares — an estimated $349K sold.

JP Morgan Private Wealth Advisors first reported a position in CRNX in Q4 2022 and held it in 3 quarters. The position peaked at $352K in Q4 2022. 171 funds tracked by Wall St. Rank hold CRNX as of Q3 2023.

  • JP Morgan Private Wealth Advisors reported no remaining Crinetics Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 19,354 Crinetics Pharmaceuticals shares in Q3 2023, an estimated $349K.
  • JP Morgan Private Wealth Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • JP Morgan Private Wealth Advisors's Crinetics Pharmaceuticals position peaked at $352K in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.